Skip to main content English


Wolf Eilenberg
Wolf Eilenberg, MD, PhD, FEBVs

Department of General Surgery (Division of Vascular Surgery)
Position: Senior physician

ORCID: 0000-0002-9322-6193
T +43 1 40400 56210

Further Information


Aortic Aneurysm, Abdominal; Biomarkers, Pharmacological; Carotid Artery Diseases; Randomized Controlled Trial

Research group(s)

Research interests

W. Eilenberg is a dedicated Consultant at the Division of Vascular Surgery, Department of General Surgery, and has conducted his PhD project on the role of neutrophils in carotid disease, with a special focus on inflammatory components. In the last years, he has extended his research to the role of neutrophils and NETs in abdominal aortic aneurysms (AAAs). Furthermore, he widen his research area on randomized control trials in AAA, presently metformin as “old medication, novel indication” with a Horizon 2020 grant application as the consortium leader with 10 international centers like Stanford University and Uppsala University. Ongoing since 2018 W. Eilenberg is the project leader of the Vienna MetAAA-trial, the first randomized controlled trial of Metformin in non-diabetic AAA. Since October 2020 he is the project leader of the Aortic PhD Fellowship “Novel Endovascular Devices in an Artificial circulatory specialized Vascular Model in stentgrafts and bridging stents”. His central clinical and research expertise inherits translational atherosclerosis and AAA research including complex aortic endovascular repair.

Techniques, methods & infrastructure

Translational research and multi-center clincial trials:

Mouse models for AAA, analyzing novel biomarkers for Neutrophil extracellular traps, translational analyis of new biomarkers in AAA disease through biobanking, consortium leader of an international multi-centre study in 8 different countries;

Endovascular complex repair: high volume center mit evolution of novel operation techniques;

Selected publications

  1. Eilenberg, W. et al., 2016. Neutrophil Gelatinase-Associated Lipocalin (NGAL) is Associated with Symptomatic Carotid Atherosclerosis and Drives Pro-inflammatory State In'
  2. Eilenberg, W. et al., 2017. NGAL and MMP-9/NGAL as biomarkers of plaque vulnerability and targets of statins in patients with carotid atherosclerosis. Clinical Chemistry and Laboratory Medicine (CCLM), 56(1). Available at:
  3. Eilenberg, W. et al., 2017. Neutrophil gelatinase associated lipocalin (NGAL) is elevated in type 2 diabetics with carotid artery stenosis and reduced under metformin treatment. Cardiovascular Diabetology, 16(1). Available at:
  4. Eilenberg, W. et al., 2019. Neutrophil Gelatinase Associated Lipocalin (NGAL) for Identification of Unstable Plaques in Patients with Asymptomatic Carotid Stenosis. European Journal of Vascular and Endovascular Surgery, 57(6), pp.768,
  5. Györi, G.P. et al., 2019. Preoperative ultrasound improves patency and cost effectiveness in arteriovenous fistula surgery. Journal of Vascular Surgery, 69(2), pp.526,